Anatol Kreitzer, Chief Discovery Officer at MapLight Therapeutics, Inc. (MPLT), sold 36,284 shares at $36.13 ($1.3M) on 2026-07-15, disclosed to the SEC on 2026-07-20.
Scheduled sale ($1.3M) by Chief Discovery Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.13 | 5,545 | $200K | 14.9% |
| 2 | $36.94 | 4,510 | $167K | 12.4% |
| 3 | $36.66 | 7,464 | $274K | 20.3% |
| 4 | $37.44 | 1,592 | $60K | 4.4% |
| 5 | $37.05 | 2,833 | $105K | 7.8% |
| 6 | $37.70 | 14,140 |
| $533K |
| 39.6% |
| 7 | $38.39 | 200 | $8K | 0.6% |
| Total | $37.09 avg | 36,284 | $1.3M | 100% |
| Filing → |
| MPLT | SELL | 2026-04-17 | $88K | — | Filing → |